 |
|
Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes
L. Kristin Newby, MD;
Arni Kristinsson, MD;
Manjushri V. Bhapkar, MS;
Philip E. Aylward, MD;
Alexios P. Dimas, MD;
Werner W. Klein, MD;
Darren K. McGuire, MD;
David J. Moliterno, MD;
Freek W. A. Verheugt, MD;
W. Douglas Weaver, MD;
Robert M. Califf, MD
JAMA. 2002;287:3087-3095.
Context The secondary prevention benefit of therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has been clearly demonstrated; however, the role of early initiation of statins after acute coronary syndromes (ACSs) is unknown.
Objective To evaluate the association of early statin initiation ( 7 days) after ACS with 90-day and 1-year outcomes.
Design Observational cohort from databases of 2 randomized clinical trials, SYMPHONY and 2nd SYMPHONY.
Setting Nine hundred thirty-one clinical centers in 37 countries.
Patients A total of 12 365 ACS patients randomized from August 1997 to August 1999 who were not taking statins prior to the index ACS and who either started statin therapy early (median, 2.0 [interquartile range, 1.0-3.1] days after ACS; n = 3952) or survived more than 5 days after ACS and never received statin therapy (n = 8413).
Main Outcome Measures Ninety-day incidence of death; death or myocardial infarction (MI); and death, MI, or severe recurrent ischemia; as well as 1-year incidence of death.
Results Ninety-day and 1-year unadjusted mortality comparison suggested early statin benefit (1.2% for early statins vs 2.1% for no statins; hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.42-0.81 for 90-day comparisons and 2.3% for early statins vs 4.4% for no statins; HR, 0.52; 95% CI, 0.40-0.68 for 1-year comparison). However, no benefit was evident for 90-day death or MI (6.5% vs 6.9%; HR, 0.95; 95% CI, 0.82-1.11) or death, MI, or severe recurrent ischemia (9.2% vs 8.9%; HR, 1.04; 95% CI, 0.92-1.18). After propensity and covariate adjustment, there were no 90-day or 1-year differences between the early-statin group and the no-statin group. The 90-day adjusted HR for death was 1.08 (95% CI, 0.75-1.56); for death or MI, 1.08 (95% CI, 0.91-1.29); and for death, MI, or severe recurrent ischemia, 1.15 (95% CI, 0.99-1.34). One-year mortality-adjusted HR was 0.99 (95% CI, 0.73-1.33). Among 2711 patients with core laboratory lipid analysis, early statin was associated with higher adjusted risk for death or death or MI at cholesterol levels below treatment guidelines but was more favorable at higher levels.
Conclusions In this study, there was no relationship between early initiation of statin therapy and improved outcomes although our subset analysis suggests that outcomes after early statin initiation may vary with cholesterol levels. Confirmation of early treatment effects of statins on outcomes awaits the results of adequately powered randomized clinical trials.
Author Affiliations: Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (Drs Newby and Califf and Ms Bhapkar); Department of Cardiology, Landspitalinn University Hospital, Reykjavik, Iceland (Dr Kristinsson); Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford Park, Australia (Dr Aylward); Department of Cardiology, Hygeia Hospital, Athens, Greece (Dr Dimas); Kardiologische Abteilung Medizinische Universitaetsklinik, Graz, Austria (Dr Klein); Department of Cardiology, University of Texas-Southwestern Medical Center, Dallas (Dr McGuire); Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Moliterno); Academisch Ziekenhuis Nijmegen, Nijmegen, the Netherlands (Dr Verheugt); and Division of Cardiology, Henry Ford Medical Center, Detroit, Mich (Dr Weaver).
RELATED ARTICLES
Estimating Treatment Effects From Observational Data: Dissonant and Resonant Notes From the SYMPHONY Trials
Karin B. Michels and Eugene Braunwald
JAMA. 2002;287(23):3130-3132.
EXTRACT
| FULL TEXT
June 19, 2002
JAMA. 2002;287(23):3153-3154.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)
Montalescot et al.
Eur Heart J 2007;28:1409-1417.
ABSTRACT
| FULL TEXT
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention: Results of the ARMYDA-ACS Randomized Trial
Patti et al.
J Am Coll Cardiol 2007;49:1272-1278.
ABSTRACT
| FULL TEXT
Geriatric Heart Failure, Depression, and Nursing Home Admission: An Observational Study Using Propensity Score Analysis
Ahmed et al.
AJGP 2006;14:867-875.
ABSTRACT
| FULL TEXT
Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes
Lenderink et al.
Eur Heart J 2006;27:1799-1804.
ABSTRACT
| FULL TEXT
Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.
Briel et al.
JAMA 2006;295:2046-2056.
ABSTRACT
| FULL TEXT
In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes: Maximizing the Early and Long-term Benefits
Fonarow
Chest 2005;128:3641-3651.
ABSTRACT
| FULL TEXT
In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications: An Analysis From the Acute Decompensated Heart Failure National Registry (ADHERE)
Abraham et al.
J Am Coll Cardiol 2005;46:57-64.
ABSTRACT
| FULL TEXT
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial
de Lemos et al.
JAMA 2004;292:1307-1316.
ABSTRACT
| FULL TEXT
Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study
Okazaki et al.
Circulation 2004;110:1061-1068.
ABSTRACT
| FULL TEXT
Management of the acute coronary syndrome patient
Waters and Khush
Eur Heart J Suppl 2004;6:C49-C57.
ABSTRACT
| FULL TEXT
Observational Studies of Treatment Effectiveness: Some Cautions
Laupacis and Mamdani
ANN INTERN MED 2004;140:923-924.
FULL TEXT
Coronary Event Secondary Prevention with Statins Irrespective of LDL-Cholesterol
Kerst and Mauro
The Annals of Pharmacotherapy 2004;38:1060-1064.
ABSTRACT
| FULL TEXT
Do statins play a role in the early management of the acute coronary syndrome?
Sacks
Eur Heart J Suppl 2004;6:A32-A36.
ABSTRACT
| FULL TEXT
Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes
Mukherjee et al.
Circulation 2004;109:745-749.
ABSTRACT
| FULL TEXT
International variation in the use of evidence-based medicines for acute coronary syndromes
Kramer et al.
Eur Heart J 2003;24:2133-2141.
ABSTRACT
| FULL TEXT
Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction
Braunwald
Circulation 2003;108:III-28-37.
ABSTRACT
| FULL TEXT
Lipid-lowering therapy for prevention of ventricular tachyarrhythmias
Anderson
J Am Coll Cardiol 2003;42:88-92.
FULL TEXT
Review: Lipid lowering drugs, inflammation and cardiovascular disease
Schachter
British Journal of Diabetes & Vascular Disease 2003;3:178-182.
ABSTRACT
Do statins confer early benefit after acute coronary syndromes? The results from FLORIDA
Varosy and Waters
Eur Heart J 2002;23:1893-1896.
Early Statin Therapy May Not Benefit ACS Patients
Journal Watch Cardiology 2002;2002:2-2.
FULL TEXT
Routine Early Statin Therapy After Acute Coronary Syndrome?
JWatch General 2002;2002:2-2.
FULL TEXT
Estimating Treatment Effects From Observational Data: Dissonant and Resonant Notes From the SYMPHONY Trials
Michels and Braunwald
JAMA 2002;287:3130-3132.
FULL TEXT
|
